Skip to main content

Merck to Acquire Sotatercept-Maker Acceleron - Here Are Acceleron's Biggest Products

Publish date:
Video Rating:
Video Duration:

Merck  (MRK ) - Get Merck & Co., Inc. Reportis acquiring Acceleron Pharma  (XLRN) - Get Acceleron Pharma Inc Report in a deal valued at about $11.5 billion, paying $180 per share in cash. The two companies made that announcement on Thursday.

“Strategic business development is a top priority for Merck as we look to drive sustainable growth and further bolster and balance our pipeline with breakthrough science,” said Merck CEO Rob Davis. “Acceleron’s innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s proud legacy in cardiovascular disease.”

Founded in 2003, the Massachusetts-based biopharmaceutical company focuses on therapeutics that treat serious and rare diseases. The company is also developing a sotatercept drug aimed at treating pulmonary hypertension.

“We believe Merck is well-positioned to apply its industry-leading clinical and commercial capabilities to harness the potential of sotatercept as we join together to help make an impact on cardiopulmonary disease for the benefit of patients," said Acceleron CEO Habib Dable. 

The company also produces Reblozyl, a drug that is used for the treatment of anemia in certain blood disorders.

The Merck-Acceleron Pharma deal is expected to close in the fourth quarter of 2021.

Related Videos